1d agoBusiness InsiderBULLISH 63Earnings
Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17
Belite Bio press release (BLTE): Q3 Non-GAAP EPS of -$0.60 beats by $0.17.As of September 30, 2026, the Company had $271.3 million in cash and cash...
Archived explainer. For the current picture see today's BLTE page.
Why Is BELITE BIO INC ADR (BLTE) Stock Up Today?
By the Top Tier Newswire AI Desk · November 12, 2026 at 3:58 PM ET · reviewed against 3 wire stories
BELITE BIO INC ADR (BLTE) is up +9.59% in the latest session. Our newswire has captured 3 stories on BLTE across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Belite Bio (BLTE) shares rose 9.59% to $170.89, driven by a third-quarter earnings beat and regulatory progress for its lead candidate. The company reported non-GAAP earnings per share of negative $0.60, exceeding the consensus estimate of negative $0.77 by $0.17.
What Happened
The primary catalyst for the move was the release of unaudited third-quarter 2026 financial results. Belite Bio reported a non-GAAP EPS of negative $0.60, which beat the consensus estimate of negative $0.77. The company also disclosed that it held $271.3 million in cash and cash equivalents as of September 30, 2026.
Regulatory developments further supported the stock’s performance. The U.S. Food and Drug Administration granted priority review to the New Drug Application for tinlarebant in Stargardt disease type 1 in August 2026. This designation established a Prescription Drug User Fee Act target date for the approval decision. Additionally, the company announced an uplisting to the Nasdaq Global Select Market.
What The Data Shows
The stock opened at $157.54, a 1.0% gap up from the prior close of $155.94. Intraday trading saw the stock hit a session low of $149.78 at 9:30 AM ET before climbing to a session high of $170.89 at 3:55 PM ET. Volume reached 0.4 million shares, which is 2.0 times the three-month daily average.
Fundamentals indicate a market capitalization of $6.3 billion with trailing twelve-month earnings per share of negative $2.74. The stock trades within a 52-week range of $102.00 to $200.00. Recent insider activity shows three sales totaling $32.0 million over the last 90 days, with no buys recorded. The most recent sale was filed on October 5, 2026. Over the last eight sessions, the stock had moved up 1.5% prior to today’s surge.
What To Watch
Investors will monitor the company’s upcoming webcast scheduled for November 12, 2026, to discuss the third-quarter results in greater detail.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BLTE by the numbers
Last: $170.89Session: +9.59%7 sessions: +11.69%Coverage: 3 stories / 2 sourcesAI sentiment: 50/100 (mixed)Mkt cap: $6.3B52w: $102.00 to $200.00
The headlines behind the move
1d agoThe FlyBEARISH 22Earnings
Belite Bio reports Q3 non-GAAP EPS (26c), consensus (77c)
1d agoBusiness InsiderBULLISH 64Earnings
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BLTE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BLTE move explainers: 2026-11-13 · 2026-11-12 · 2026-09-08 · 2026-09-04